BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23040684)

  • 1. Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
    Francois E; Smith D; Dahan L; Michel C; Perrier H; Mari V; Seitz JF; Follana P; Evesque L; Chamorey E
    J Chemother; 2012 Aug; 24(4):207-11. PubMed ID: 23040684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
    Vormittag L; Kornek GV; Gruhsmann B; Lenauer A; Föger A; Depisch D; Lang F; Scheithauer W
    Anticancer Drugs; 2007 Jul; 18(6):709-12. PubMed ID: 17762401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer.
    Michalaki V; Gennatas S; Gennatas C
    J BUON; 2010; 15(2):270-3. PubMed ID: 20658720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
    Alkis N; Demirci U; Benekli M; Yilmaz U; Isikdogan A; Sevinc A; Ozdemir NY; Koca D; Yetisyigit T; Kaplan MA; Uncu D; Unek T; Gumus M
    J BUON; 2011; 16(1):80-3. PubMed ID: 21674854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
    Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
    Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
    Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
    Bozkurt O; Karaca H; Ciltas A; Kaplan MA; Benekli M; Sevinc A; Demirci U; Eren T; Kodaz H; Isikdogan A; Ozkan M; Buyukberber S
    Asian Pac J Cancer Prev; 2014; 15(4):1845-9. PubMed ID: 24641419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
    Chayahara N; Tamura T; Yamamori M; Kadowaki Y; Okuno T; Miki I; Tsuda M; Nishisaki H; Maeda T; Inoue Y; Okumura K; Azuma T; Kasuga M; Sakaeda T; Hirai M
    Am J Clin Oncol; 2009 Feb; 32(1):56-60. PubMed ID: 19194126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
    Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
    Méndez M; Alfonso PG; Pujol E; González E; Castañon C; Cerezuela P; López-Mateos Y; Cruz JJ
    Invest New Drugs; 2005 Jun; 23(3):243-51. PubMed ID: 15868381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
    Tsunoda A; Nakao K; Watanabe M
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1065-8. PubMed ID: 20567109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
    Hochster HS; Luo W; Popa EC; Lyman BT; Mulcahy M; Beatty PA; Benson AB
    J Clin Oncol; 2007 Dec; 25(34):5397-402. PubMed ID: 18048821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
    Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer.
    Shibahara K; Yamamoto M; Kakeji Y; Sakata H; Maehara Y
    Anticancer Res; 2008; 28(3B):1779-83. PubMed ID: 18630459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
    Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
    PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer].
    Sadahiro S; Suzuki T; Maeda Y; Makuuchi H; Murayama C
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):333-6. PubMed ID: 16531713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
    Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
    Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit of oral tegafur/uracil and leucovorin as a first line therapy for elderly patients with advanced or metastatic colorectal cancer.
    Murata K; Yamamoto H; Fukunaga M; Kato T; Ohnishi T; Uemura Y; Ohta H; Kimura F; Ohue M; Nezu R; Sekimoto M; Ikeda M; Mizushimaz T; Doki Y; Mori M;
    Hepatogastroenterology; 2014; 61(129):94-8. PubMed ID: 24895801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
    Rosati G; Cordio S; Tucci A; Blanco G; Bordonaro R; Reggiardo G; Manzione L
    Oncology; 2005; 69(2):122-9. PubMed ID: 16118508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.